SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Image of Houston downtown park and skyline in the morning
Business
Houston’s Life Sciences Scene Continues Boosting Its Reputation
While Houston isn’t yet on the same level as major life sciences hubs, it has plenty to offer and room to grow, according to CNS Pharmaceuticals, RadioMedix and Greater Houston Partnership executives.
March 13, 2025
 · 
6 min read
 · 
Angela Gabriel
piggy bank behind umbrella to cover and protect from downturn arrow. Protection or defensive stock in economy crisis
Mergers & acquisitions
Acelyrin Adopts Poison Pill to Ward Off Tang Capital Buy
The move by Acelyrin’s board comes as the venture capital firm has taken larger and larger stakes in the company in an attempt to disrupt a merger with Alumis.
March 13, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
Business
“Perfect Patient” Industry Burdens; Exits and Investment in Women’s Health
In this episode of Denatured, BioSpace’s Head of Insights Lori Ellis and Miruna Sasu, CEO of COTA, discuss the challenges of inclusion and exclusion criteria of clinical trial patients, and reflect on current investment approaches around women’s health.
March 13, 2025
 · 
1 min read
 · 
Lori Ellis
Amgen sign at its headquarters in Thousand Oaks, California, USA.
Autoimmune disease
Amgen’s Uplizna Deepens Response Against Myasthenia Gravis at 1 Year
With what analysts are calling “strong” data, Amgen plans to file a regulatory submission for Uplizna, currently approved for a rare ocular autoimmune disorder, in myasthenia gravis, in the first half of 2025.
March 13, 2025
 · 
1 min read
 · 
Tristan Manalac
A human hand showing dollar golden coins in the jar with a colored background. Collage Art of finance
Manufacturing
J&J, Legend Pump $150M Into Manufacturing in Bid to Double Carvykti Production
Johnson & Johnson and Legend Biotech hope to hit blockbuster status for Carvykti this year.
March 13, 2025
 · 
2 min read
 · 
Tristan Manalac
Illustration of two arrows merging into one
Mergers & acquisitions
Troubled Drugmakers Mallinckrodt, Endo Officially Announce $6.7B Merger
Both Mallinckrodt and Endo have previously declared bankruptcy, linked to opioid-related lawsuits.
March 13, 2025
 · 
2 min read
 · 
Tristan Manalac
Businessman holding a dart aiming at the target - business targeting, aiming, focus concept. Art collage.
Infectious disease
Gilead, GSK-ViiV Move Ahead With Long-Acting HIV Options Following Early-Stage Readouts
Gilead plans to go straight to Phase III studies for once-yearly lenacapavir, while GSK and ViiV will push forward with their long-acting antivirals after touting positive early-stage results.
March 12, 2025
 · 
2 min read
 · 
Tristan Manalac
Pictured: Merck building and sign in Silicon Valley
Vaccines
Good Day for Gardasil as Merck Wins Safety Suit, Drops $1B for Manufacturing Push
According to Judge Kenneth Bell, there is a lack of evidence to conclude that Merck willingly misrepresented the safety of its HPV vaccine Gardasil to patients and prescribers.
March 12, 2025
 · 
2 min read
 · 
Tristan Manalac
Concept of money prize. Vector illustration. Halftone hand holds bouquet of money flowers. Gift prize, donation, earnings, bonus or cashback concept. Retro poster or banner. Creative trend collage.
Weight loss
Roche Makes Another Obesity Play With Potential $5.3B Amylin Pact With Zealand
Roche and Zealand plan to study petrelintide as a monotherapy and in combination with CT-388, a dual agonist of the GLP-1 and GIP receptors that Roche picked up in its recent acquisition of Carmot Therapeutics.
March 12, 2025
 · 
2 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS